Rhumbline Advisers Belite Bio, Inc Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Belite Bio, Inc stock. As of the latest transaction made, Rhumbline Advisers holds 1,435 shares of BLTE stock, worth $92,012. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,435Holding current value
$92,012% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BLTE
# of Institutions
16Shares Held
78.7KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.1KShares$1.29 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC13.5KShares$862,4780.0% of portfolio
-
Marshall Wace, LLP London, X08.49KShares$544,1220.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$429,6040.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.46KShares$414,2150.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.59B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...